Liver Unit Hospital Clínic. Institut D'investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas (Ciberehd), Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, and Department for Clinical Research, University of Southern Denmark, Odense, Denmark.
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2567-2576.e6. doi: 10.1016/j.cgh.2021.12.034. Epub 2021 Dec 29.
BACKGROUND & AIMS: Fibrosis-4 (FIB-4) and the nonalcoholic fatty liver disease fibrosis score (NFS) are the 2 most popular noninvasive blood-based serum tests proposed for widespread fibrosis screening. We therefore aimed to describe the accuracy of FIB-4 and NFS to detect elevated liver stiffness as an indicator of hepatic fibrosis in low-prevalence populations.
This study included a total of 5129 patients with concomitant measurement of FIB-4, NFS, and liver stiffness measurement (LSM) by Fibroscan (Echosens, France) from 5 independent population-based cohorts from Spain, Hong Kong, Denmark, England, and France; 3979 participants from the general population and 1150 from at-risk cohorts due to alcohol, diabetes, or obesity. We correlated LSM with FIB-4 and NFS, and calculated pre- and post-test predictive values of FIB-4 and NFS to detect elevated LSM at 8 kPa and 12 kPa cutoffs. The mean age was 53 ± 12 years, the mean body mass index was 27 ± 5 kg/m, and 2439 (57%) were women. One in 10 patients (552; 11%) had liver stiffness ≥8 kPa, but 239 of those (43%) had a normal FIB-4, and 171 (31%) had normal NFS. The proportion of false-negatives was higher in at-risk patients than the general population. FIB-4 was false-negative in 11% of diabetic subjects, compared with 2.5% false-negatives with NFS. Waist circumference outperformed FIB-4 and NFS for detecting LSM ≥8 kPa in the general population. Almost one-third (28%-29%) of elevated FIB-4/NFS were false-positive in both the general population and at-risk cohorts.
FIB-4 and NFS are suboptimal for screening purposes due to a high risk of overdiagnosis and a non-negligible percentage of false-negatives, especially in patients with risk factors for chronic liver disease. Waist circumference emerged as a potential first step to identify patients at risk for liver fibrosis in the general population.
纤维化 4 指数(FIB-4)和非酒精性脂肪性肝病纤维化评分(NFS)是非侵入性血清学检测中最常用的两种方法,用于广泛的纤维化筛查。因此,本研究旨在描述 FIB-4 和 NFS 检测低患病率人群中肝纤维化的准确性,以确定肝硬度升高是否为肝纤维化的指标。
本研究共纳入了来自西班牙、中国香港、丹麦、英国和法国的 5 个独立的基于人群的队列的 5129 名患者,这些患者同时接受了 FIB-4、NFS 和肝脏硬度测量(LSM)的检测,其中 3979 名来自普通人群,1150 名来自因饮酒、糖尿病或肥胖而处于高危状态的人群。我们将 LSM 与 FIB-4 和 NFS 进行相关性分析,并计算 FIB-4 和 NFS 检测 LSM 升高的阳性预测值和阴性预测值,截断值为 8 kPa 和 12 kPa。患者的平均年龄为 53±12 岁,平均体重指数为 27±5 kg/m2,2439 名(57%)为女性。10 名患者中就有 1 名(552 名;11%)肝硬度≥8 kPa,但其中 239 名(43%)FIB-4 正常,171 名(31%)NFS 正常。高危人群的假阴性率高于普通人群。在糖尿病患者中,FIB-4 的假阴性率为 11%,而 NFS 的假阴性率为 2.5%。在普通人群中,腰围检测对 LSM≥8 kPa 的检测性能优于 FIB-4 和 NFS。在普通人群和高危人群中,几乎有三分之一(28%-29%)的 FIB-4/NFS 升高为假阳性。
由于存在较高的过度诊断风险和不可忽视的假阴性率,FIB-4 和 NFS 并不适合用于筛查目的,尤其是在存在慢性肝病危险因素的患者中。腰围可能成为普通人群中识别肝纤维化高危人群的第一步。